Syncromune, Inc., A Clinical Stage Biopharmaceutical Company Focused On The Development Of Combination Intratumoral Immunotherapy Announced Today That The Company Has Signed An Exclusive Worldwide License Agreement For Yh002 (Ox40 Antibody) And Two Other Active Ingredients With Eucure (Beijing) Biopharma Co., Ltd. (
